tiprankstipranks
Trending News
More News >
Avalo Therapeutics (AVTX)
NASDAQ:AVTX
US Market

Avalo Therapeutics (AVTX) Financial Statements

Compare
1,037 Followers

Avalo Therapeutics Financial Overview

Avalo Therapeutics's market cap is currently $297.31M. The company's EPS TTM is $-2.19; its P/E ratio is -1.71; Avalo Therapeutics is scheduled to report earnings on November 6, 2025, and the estimated EPS forecast is $-1.46. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue$ 441.00K$ 1.92M$ 18.05M$ 5.40M$ 6.70M
Gross Profit$ 807.00K$ 640.00K$ 14.62M$ 3.91M$ 6.40M
Operating Income$ -68.51M$ -27.35M$ -37.44M$ -82.13M$ 0.00
EBITDA$ -68.34M$ -23.29M$ -37.27M$ -80.48M$ -45.45M
Net Income$ -35.13M$ -31.54M$ -41.66M$ -84.38M$ -63.50M
Balance Sheet
Cash & Short-Term Investments$ 134.55M$ 7.42M$ 13.17M$ 54.59M$ 18.92M
Total Assets$ 150.73M$ 20.99M$ 33.37M$ 80.21M$ 43.76M
Total Debt$ 568.00K$ 537.00K$ 19.95M$ 33.32M$ 426.00K
Net Debt$ -133.98M$ -6.88M$ 6.78M$ -21.27M$ -18.49M
Total Liabilities$ 17.70M$ 13.69M$ 44.28M$ 57.13M$ 19.19M
Stockholders' Equity$ 133.03M$ 7.30M$ -10.91M$ 23.08M$ 24.56M
Cash Flow
Free Cash Flow$ -49.06M$ -30.84M$ -26.85M$ -71.00M$ -40.60M
Operating Cash Flow$ -49.06M$ -30.68M$ -26.75M$ -70.89M$ -40.54M
Investing Cash Flow$ 356.00K$ -133.00K$ -95.00K$ -113.00K$ 11.13M
Financing Cash Flow$ 175.85M$ 25.04M$ -14.70M$ 106.76M$ 44.78M
Currency in USD

Avalo Therapeutics Earnings and Revenue History

Avalo Therapeutics Debt to Assets

Avalo Therapeutics Cash Flow

Avalo Therapeutics Forecast EPS vs Actual EPS